Earlier Alzheimer’s detection is only progress if it leads to action

In Scotland, a new study is bringing blood-based markers of Alzheimer’s disease (AD) testing into more than 50 GP practices to understand how it could work in primary healthcare.

Separately, international research has suggested that a blood biomarker may help identify people at greater risk of developing cognitive impairment several years before symptoms appear.

Both developments are encouraging. For patients and families, the possibility of a quicker, less invasive route to assessment could help reduce some of the uncertainty in reaching a diagnosis.

For researchers, it could also make it easier to identify people who may be suitable for clinical trials and support the development of future treatments.

They also bring a much bigger question into focus: if we develop the ability to identify Alzheimer’s earlier, are our health systems ready to respond?

A blood test isn’t an endpoint. It’s the beginning of a pathway that must provide clear information, further assessment where needed, clinical support and an honest conversation about the options available for patients.

That matters particularly when testing moves towards people who may have few, or even no, noticeable symptoms. A result may well indicate an increased risk, but it can’t predict an individual’s future with certainty. We therefore need to think carefully about how results are explained, how people are supported and what practical choices follow. The evidence does not yet support routine screening of people without symptoms.

The treatment and management of Alzheimer’s is entering a period of profound change. A wide range of therapies are being investigated, targeting different aspects of the disease and offering the prospect of intervention at different stages. Pharmaceutical treatments are already demonstrating the potential to alter the course of Alzheimer’s, and the range of approaches in clinicians’ armouries could expand significantly in the years ahead.

The potential benefits of any treatments extend well beyond the individual patient. Drugs that help people retain independence and quality of life for longer could ease some of the enormous pressures experienced by families and unpaid carers. They could also reduce or delay the need for more intensive health and social care, changing how clinical systems manage a condition, the impact of which is felt across households, communities and public services.

However, scientific progress will not translate automatically into population-wide benefit. New treatments will bring different requirements for identifying suitable patients, confirming diagnoses, monitoring safety and measuring response. Some may require hospital visits, specialist oversight or additional scans. Others may be easier to administer through existing services. Each will carry implications for affordability, workforce, infrastructure and equitable access.

This is particularly important because Alzheimer’s is already underserved by existing diagnosis and treatment pathways. Too many people receive a diagnosis late, experience long waits for specialist assessment, or never enter a pathway at all. Introducing potentially transformative treatments into a system with these constraints will require fundamental adjustment.

Health systems must also ensure that rural and remote communities have the same opportunity to benefit as those living close to specialist centres.

Scotland is well placed to be a testbed for this next stage. The new GP-based study is important precisely because it moves the conversation from what’s scientifically demonstrated to what can be delivered in real clinical practice. It can help us understand not only whether blood tests improve diagnosis, but how they connect with the services, support and treatments that should follow.

The opportunity is to have a conversation that helps us prepare now, while the science and treatment landscape continue to develop. Diagnostics, workforce planning, treatment assessment, funding and service design can’t be treated as separate conversations or addressed one after another.

Earlier detection could transform Alzheimer’s care for the better. Success will not be measured by how many people are tested, or even by how many new treatments become available. It will be measured by whether scientific progress leads to earlier, equitable and meaningful action for patients and families.

Dr Sonya Miller is TauRx Medical Director